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Abstract
Background: The EORTC QLQ-C30 is one of the most widely used quality of life questionnaires in cancer research.
Availability of thresholds for clinical importance for the individual questionnaire domains could help to increase its
interpretability. The aim of our study was to identify thresholds for clinical importance for four EORTC QLQ-C30
scales: Physical Functioning (PF), Emotional Functioning (EF), Pain (PA) and Fatigue (FA).
Methods: We recruited adult cancer patients from Austria, the Netherlands, Poland and the UK. No restrictions
were placed on diagnosis or type or stage of treatment. Patients completed the QLQ-C30 and three anchor items
reflecting potential attributes of clinically important levels of PF, EF, PA and FA. We merged the anchor items
assessing perceived burden, limitations in daily activities and need for help into a dichotomous external criterion to
estimate thresholds for clinical importance using Receiver Operator Characteristic (ROC) analysis.
Results: In our sample of 548 cancer patients (mean age 60.6 years; 54 % female), the QLQ-C30 scales showed high
diagnostic accuracy in identifying patients reporting burden, limitations and/or need for help related to PF, EF, PA
and FA. All areas under the curve were above 0.86.
Conclusions: We were able to estimate thresholds for clinical importance for four QLQ-C30 scales. When used in
daily clinical practice, these thresholds can help to identify patients with clinically important problems requiring
further exploration and possibly intervention by health care professionals.
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Background
For the evaluation of cancer treatments, parameters such
as survival time or time to tumor progression are the
most common primary outcomes. In addition, assess-
ment of patient-reported physical or psychosocial symp-
tom burden has gained considerable importance within
clinical trials [1–4] and clinical practice [5]. Patient-
reported outcomes (PROs) can add important informa-
tion to clinical trials and medical decision making [6].
To improve the interpretation of PRO data collected
within clinical trials, research efforts have focused on
thresholds like minimally important differences (MIDs)
or minimally important changes (MICs) over time. An
MID or MIC is the smallest difference or change in PRO
score points considered to be of clinical relevance [7].
Such thresholds related to change scores help to inter-
pret the impact of disease and treatment in a relative
manner by comparison to previous assessments of the
same patient or to other patient groups. However, they
do not aid in the interpretation of absolute scores, i.e.
scores obtained from an individual patient or a patient
group at a single time point. To better understand what
a given score from an individual patient or an average
score from a patient group means, researchers have
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started to develop clinical thresholds that allow identifi-
cation of clinically important symptom burden or
impairment [8, 9].
The EORTC QLQ-C30 [10] is one of the most widely
used health-related quality of life (HRQOL) question-
naires in cancer research. It assesses important function-
ing domains (e.g. physical, emotional, role) and common
cancer symptoms (e.g. fatigue, pain, nausea/vomiting,
appetite loss). Current approaches to defining clinical
thresholds for the EORTC QLQ-C30 vary substantially
and each has its own strengths and weaknesses. The
simplest and most straight-forward approach is to rely
on the wording of the item or response categories them-
selves, and classify a patient as having a clinically im-
portant problem if s/he responds with at least “a little”
for any given item or domain assessed on the 4 point re-
sponse scale (i.e. “not at all,” “a little,” “quite a bit,” and
“very much”) [11, 12]. This approach can be problem-
atic as it uses the same threshold for all QLQ-C30
domains. As has been shown in Item Response The-
ory analyses [13], the QLQ-C30 items differ in item
difficulty (i.e. they assess different levels of severity of
a problem or symptom), suggesting that scores are
not directly comparable across domains. For example,
reporting “quite a bit” of vomiting probably indicates
a different symptom level than reporting “quite a bit”
of trouble with sleeping. This problem also applies to
studies using the same cut-off score as a threshold
for all domains (e.g. a score of 50 as done by Klin-
khammer et al. [14]).
Another approach is based on score distributions and
makes use of percentiles or statistics from reference
populations (often the general population). However, the
choice of a percentile or statistic is somewhat arbitrary.
In addition, if, as is commonly done [15–17], the general
population mean is used as a threshold, the resulting
percentage of patients with a clinically important prob-
lem is likely to be very high. Using the population aver-
age often means that around half of the general
population (depending on the score distributions) will be
classified as having a clinically important problem. Also,
such a definition of clinical thresholds assumes the
prevalence rate of clinically important problems is con-
stant across the various HRQOL domains.
These limitations can potentially be overcome by rely-
ing on external anchors for determining thresholds for
clinical importance. An example of this approach is the
use of patients’ ratings of their most bothersome symp-
toms or functional limitations as an external anchor. Pa-
tients could be asked to name their most bothersome
symptoms or limitations in addition to completing scales
assessing symptom or problem levels. This allows one to
determine thresholds above which patients are likely to
consider a symptom or limitation as bothersome (e.g.
using ROC analysis). Although this has clear advantages
over distribution-based thresholds, it relies on a some-
what narrow definition of clinical importance (basically
being equated with what is most “bothersome”). Also, in
previous work the number of most bothersome symp-
toms per patient has been fixed a priori [18].
In the current study, we have investigated an alterna-
tive approach to establishing thresholds for clinical sig-
nificance that does not rely on one, but rather on several
potential anchors. The objective of our study was to use
an anchor-based approach to defining thresholds for
clinical importance for four key EORTC QLQ-C30
scales: Physical Functioning (PF), Emotional Functioning
(EF), Pain (PA) and Fatigue (FA). Thresholds for clinical
importance were intended to identify symptoms and
functional health problems that require a health care
professional’s attention.
Methods
Sample
We recruited a cross-sectional sample of cancer patients
from centers in four European countries: the
Netherlands Cancer Institute (the Netherlands), Kufstein
County Hospital (Austria), the Mount Vernon Cancer
Centre and Basingstoke & North Hampshire Hospital
(the United Kingdom) and the Jagiellonian University
Medical College (Poland). To obtain a heterogeneous
sample we included any cancer patient (on- or off-
treatment) aged above 18 years. Patients were invited to
participate in the study via mail or during a clinic visit,
and were asked to complete the EORTC QLQ-C30 and
an additional questionnaire with anchor items.
Assessment instruments
EORTC QLQ-C30
The EORTC QLQ-C30 [10] is an internationally vali-
dated and widely used cancer-specific HRQOL instru-
ment. It contains five functioning scales (physical, social,
role, cognitive, and emotional functioning), eight symp-
tom scales (fatigue, nausea/vomiting, pain, dyspnea,
sleep disturbances, appetite loss, constipation, and diar-
rhea), financial impact, and overall quality of life. All
scale scores are linearly converted to range from 0 to
100. For the functioning scales and global QOL higher
scores indicate better functioning; for the symptom
scales higher scores indicate higher symptom burden.
Anchor items
An expert panel including four PRO researchers, three
psycho-oncologists, three oncologists and a biostatisti-
cian generated a set of anchor items intended to assess
the clinical importance of functional health problems
and symptoms included in the QLQ-C30. This set of an-
chor items was reviewed independently by the EORTC
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Quality of Life Group as part of a grant review process
and additionally underwent external anonymous peer re-
view within this process. The anchor items were also
presented and discussed in plenary at an EORTC Quality
of Life Group meeting. The wording of the anchor items
and the response categories were as follows:
 Has your PF/EF/FA/PA been a burden to you?
Not at all – A little – Quite a bit – Very much
 Has your PF/EF/FA/PA limited your daily activities?
Not at all – A little – Quite a bit – Very much
 Have you needed any help or care for your PF/EF/
FA/PA?
No help – A little help from family or friends –
Quite a bit of help from family or friends –
Professional help (e.g. physicians, nurses)
A functional limitation or symptom was considered to
be potentially clinically important if any of the three an-
chor items was answered positively. More specifically, a
patient was considered to have a problem of at least
“minimal clinical importance”, if s/he reported at least “a
little” for any of the three anchor items. Patients who
rated their problem/symptom as “quite a bit” or “very
much” for any anchor item were classified as having a
problem of “clinical importance”. In line with this, we
labeled the two possible thresholds to be investigated
further TMCI (Threshold for Minimal Clinical Import-
ance) and TCI (Threshold for Clinical Importance).
Statistical analysis
Sample characteristics are presented as means, standard
deviations, and absolute and relative frequencies.
In a first step we calculated prevalence rates (i.e. rela-
tive frequency of positive cases) for symptoms and func-
tioning problems in our sample based on the above
definitions of TMCI and TCI. These prevalence rates
were evaluated to decide which anchor definition (TMCI
or TCI) to employ for further analysis and development
of the final thresholds. We considered an anchor defin-
ition to be too sensitive if it resulted in the majority of
patients being classified as positive cases on multiple do-
mains. This would not be sustainable in clinical practice,
as it would require additional help and/or intervention
for too many patients.
To assess the discriminatory power of the QLQ-C30
scales, we calculated effect sizes (Cohen’s d) for the
mean QLQ-C30 scale score differences between patients
classified as having a clinically important problem and
those not so classified. To determine the diagnostic ac-
curacy of the QLQ-C30 scales with regard to the exter-
nal anchors we conducted Receiver Operating
Characteristic (ROC) analyses and calculated the Area
Under the Curve (AUC). In line with Hosmer and
Lemeshow (1989), we classified diagnostic accuracy as
follows: <0.70 poor; 0.70–0.80 acceptable; >0.80 excel-
lent [19].
Selection of threshold scores for the QLQ-C30 scales
was based primarily on Youden’s J [20], i.e. the sum of
sensitivity and specificity minus one. In case of different
thresholds showing comparable Youden’s J, we chose the
one providing higher sensitivity, as we considered sensitiv-
ity to be more important than specificity in the context of
initial screening for problems at the individual patient
level. We also calculated correlations (Spearman’s Rho)
between the three anchor items.
We used binary logistic regression analysis to investi-
gate invariance of diagnostic accuracy and stability of
thresholds across different patient groups. The regres-
sion analysis included the dichotomous external anchor
as the dependent variable, and the QLQ-C30 scale and
the grouping variables (sex, age, stage, country, treat-
ment status) as independent variables. In such a model,
the main effect of the grouping variable indicates a dif-
ference in diagnostic accuracy of the anchor-based
threshold (sensitivity/specificity) between the patient
groups. A significant interaction term (grouping variable
* scale) indicates that the optimal threshold providing
the lowest misclassification rate differs across patient
groups. To account for multiple testing in these sensitiv-
ity analyses we considered p-values below 0.01 to be sta-
tistically significant.
Results
Patient characteristics
Between October 2013 and September 2014 we re-
cruited 548 patients (236 in the Netherlands, 151 in
Austria, 100 in Poland and 61 in the UK). Mean age was
60.6 years (SD 12.3) and 54.0 % was female. The most
frequent diagnoses were breast cancer (25.7 %), colorec-
tal cancer (12.8 %) and lung cancer (11.7 %). Most pa-
tients had advanced disease (UICC stage III or IV:
61.2 %). At the time of the assessment 73.3 % of the pa-
tients were receiving anti-cancer treatment, with chemo-
therapy (24.7 %), chemotherapy and surgery (18.4 %),
and chemo- and radiotherapy (11.4 %) being the most
common treatments. Further details are given in
Table 1.
Anchor items and clinical importance
Burden, limitations or need for help were found to be
most prevalent for PF and FA. The highest percentages
of patients selecting one of the two most severe categor-
ies on the anchor items were found for limitations re-
garding FA (34.4 % of the patients answered “quite a bit”
or very much”) and burden related to PF (33.9 % of the
patients answered “quite a bit” or “very much”). Please
see Table 2 for further details. Correlations between the
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three anchor items were generally high. The domain-
specific correlations between reported burden and limi-
tations in daily activities ranged from 0.75 for emotional
functioning to 0.88 for pain. Correlations with need for
help were lower ranging from 0.56 to 0.65 for burden,
and from 0.61 to 0.72 for limitations (Table 3).
Using our definition for TMCI, we found a prevalence
rate in our sample of 77.7 % for PF, 77.3 % for FA,
61.1 % for EF, and 47.5 % for pain. As expected, using
the TCI definition, reflecting a higher degree of burden,
limitations and need for help, we found lower prevalence
rates: 41.7 % for PF, 39.2 % for FA, 28.0 % for EF, and
24.1 % for PA.
Effect sizes for mean differences between cases and
non-cases based on the TCI classification ranged from
1.56 for PF to 2.33 for PA. Further details are given in
Table 2.
The very high prevalence rates derived from the
TMCI definition indicated that those thresholds are
probably too liberal to derive meaningful prevalence
rates or to be useful for screening in daily clinical
practice. Further analyses were therefore conducted
for the TCI only.
Thresholds for the QOL scales
In the ROC analysis, the four QLQ-C30 scales showed
high diagnostic accuracy in predicting the TCI criterion.
AUC ranged from 0.86 for EF to 0.91 for PA, suggesting
excellent screening properties [19] (Fig. 1).
Based on the rationale of selecting thresholds with
high diagnostic accuracy in terms of Youden’s J and an
emphasis on sensitivity, we obtained the following cut-
off scores: PF = 83 points (sensitivity 0.87 and specificity
0.68), EF = 70 points (sensitivity 0.80 and specificity
0.76), FA = 39 points (sensitivity 0.86 and specificity
0.78), and PA = 25 points (sensitivity 0.89 and specificity
0.76). Please note that due to different scale directions
clinically important scores for PF and EF are below the
thresholds whereas for FA and PA they are above the
thresholds. Further details are given in Table 4.
Sensitivity analysis
We did not find a significant interaction between the
grouping variables (age, sex, tumour stage, treatment
status, and country) and the QLQ-C30 scores when pre-
dicting caseness, which was defined according to the
criteria for TCI. This suggests that diagnostic accuracy
(in terms of AUC) is stable across patient groups.
The main effects of the grouping variables age, sex,
tumor stage and treatment status were not statistically
significant. Analysis of the impact of country showed
that Poland differed significantly from the other coun-
tries with regard to EF (p = 0.005) and FA (p = 0.007).
For EF, a cut-off of 62 points provided the highest value
for Youden’s J for Poland and the other countries, but
sensitivity and specificity was 0.80 and 0.81 for Poland
and 0.64 and 0.89 for the other countries. Results were
similar for FA, with the same cut-off of 39 points show-
ing highest Youden’s J for both groups whereas the exact
sensitivities and specificities differed (0.83 and 0.72 for
Poland and 0.87 and 0.79 for the other countries).
Discussion
In this study we have developed clinical thresholds for
the physical functioning, emotional functioning, fatigue
and pain scales of the EORTC QLQ-C30. By using three
anchor items assessing burden, limitations and need for
help related with a specific domain, we defined an exter-
nal criterion for clinical importance. Applying this criter-
ion in our sample, we found prevalence rates for
clinically important problems ranging from 22.9 % (pain)
to 38.5 % (physical functioning).
To investigate the invariance of diagnostic accuracy
across different patient groups we conducted binary lo-
gistic regression analyses. These showed that differences
across the investigated patient subgroups were minor,
indicating invariance of the thresholds across these
groups. Based on these findings we do not recommend
Table 1 Descriptive statistics for sociodemographic and clinical
variables (n = 548)
Age: Mean (SD) 60.6 (12.3)
Range 19–89
Sex: Women 54.0 %
Men 46.0 %
Diagnosis: Breast cancer 25.7 %
Colorectal cancer 12.8 %
Lung cancer 11.7 %
Head & neck cancer 8.0 %
Prostate cancer 7.4 %
Non-Hodgkin Lymphoma 7.3 %
Stomach/Oesophagic cancer 6.6 %
Gynaecologic cancer 6.0 %
Other 14.5 %
UICC stage: I 9.9 %
II 28.9 %
III 24.4 %
IV 36.8 %
Current treatment: No treatment 26.7 %
Chemotherapy 24.7 %
Chemotherapy and surgery 18.4 %
Radio- and chemotherapy 11.4 %
Surgery and Radiotherapy 4.4 %
Surgery 4.0 %
Other 10.4 %
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using different thresholds for different subgroups
(e.g. men versus women, patients on- and off-treatment).
The invariance of thresholds is an important finding be-
cause the use of different thresholds for different patient
subgroups would be complex in daily clinical practice and
might not always be intuitively understood by health care
professionals.
In principle, the anchor items used in our study
could be used directly for screening for clinically im-
portant problems. However, using the QLQ-C30 and
the developed thresholds instead provides additional
benefits. The QLQ-C30 provides better measurement
precision, in particular with regard to changes over
time. It also allows one to relate individual patient
scores to norm/reference data available from the lit-
erature and to use the collected data for scientific
purposes. For these reasons clinicians and researchers
may prefer using thresholds for this well-validated
questionnaire over only using the anchor items from
this study.
The methodological approach most comparable to our
study is the analysis by Snyder et al. [8]. They established
cut-off scores for the QLQ-C30 using unmet needs de-
fined by dichotomised scores from the Supportive Care
Needs Survey (SCNS) as the external criterion. In their
study, the diagnostic accuracy of the six investigated
QLQ-C30 scales (PF, EF, FA, PA, role functioning and
global QOL) was found to be lower than in our study
(AUCs were between 0.56 and 0.81). More interestingly,
their thresholds were also substantially different from
ours, with the differences ranging from 10 to 20 points.
In their study, a lower symptom or functional health
score was required to qualify as a positive case. This
might be related to the use of a different anchor defin-
ition that was more sensitive than our TCI criterion. A
patient was considered a positive case if s/he had a low,
moderate or high need in a certain area, and a negative
case if s/he had a satisfied need or if the question was
not applicable. In our analysis, a more sensitive criterion
like the TMCI would have led to prevalence rates of up
Table 2 Descriptive statistics for the QLQ-C30 scales and the anchor items (n = 548)
Physical Functioning Emotional Functioning Fatigue Pain
Mean (SD) 73.9 (23.8) 73.0 (24.5) 41.8 (27.6) 24.3 (28.8)
Burden:
not at all 29.2 % 43.4 % 27.3 % 57.2 %
a little 37.0 % 35.2 % 40.5 % 25.1 %
quite a bit 24.8 % 14.2 % 23.0 % 13.5 %
very much 9.1 % 7.2 % 9.2 % 4.2 %
Limitation:
not at all 28.8 % 57.6 % 29.1 % 59.0 %
a little 38.1 % 25.5 % 36.5 % 23.1 %
quite a bit 22.0 % 11.3 % 26.3 % 13.9 %
very much 11.1 % 5.7 % 8.1 % 4.1 %
Need for help:
no help 57.1 % 66.9 % 59.7 % 71.4 %
little help (family) 21.8 % 17.0 % 23.3 % 13.1 %
quite a bit of help (family) 14.8 % 8.3 % 12.6 % 5.9 %
professional help 6.3 % 7.8 % 4.4 % 9.6 %
Prevalence TMCI 77.7 % 61.1 % 77.3 % 47.5 %
Prevalence TCI 41.7 % 28.0 % 39.2 % 24.1 %
Effect size TCIa 1.56 1.69 1.80 2.33
aEffect size given as Cohen’s d for comparing negative and positive cases as defined by the criteria for moderate/severe problems
Table 3 Correlations between anchor items (Spearman’s Rho)
Physical Functioning Emotional Functioning Fatigue Pain
Burden – limitations 0.83 0.75 0.83 0.88
Burden – help 0.56 0.62 0.59 0.65
Limitations – help 0.61 0.64 0.63 0.72
All p < 0.001
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to 78 %. In addition to this difference in the definition of
the anchor items, the differences observed in optimal
thresholds in their study and ours might indicate cross-
cultural influences (American versus European cancer
patients).
In another study by Snyder and colleagues [18], the
QLQ-C30 was also shown to be capable of accurately
identifying a patient’s most bothersome issues. For the
prediction of these most bothersome issues, sensitivity
and specificity for functional health were 0.75 and 0.64, re-
spectively while for symptoms classification accuracy was
somewhat better (sensitivity = 0.83; specificity = 0.76).
Interestingly, the authors also found that diagnostic
performance of change scores was lower than that for ab-
solute scores. This is in line with a recent analysis of Sny-
der et al. [9] that showed that a change in patients’ QLQ-
C30 scores does not relate consistently to a change in pa-
tients’ supportive care needs. Such findings support our
approach relying on absolute scores rather than on change
scores for identification of clinically important problems.
A limitation of our study is that the anchor items and
the definitions for (minimal) clinical importance were
based on input from an expert panel only. However, the
three anchors that we employed in our study reflect
characteristics of patients’ symptom burden and func-
tional health limitations that are typically assessed in
Fig. 1 Receiver Operator Characteristic curves for the threshold for clinical importance
Table 4 Results from the Receiver Operator Characteristics (ROC) analysis and TCI
Area under curve 95 % confidence interval Threshold for Clinical
Importance (TCI)
Sensitivity/Specificity
Physical Functioning 0.87 (0.83–0.90) 83 (0.87/0.68)
Emotional Functioning 0.86 (0.82–0.90) 70 (0.80/0.76)
Fatigue 0.89 (0.86–0.91) 39 (0.86/0.78)
Pain 0.91 (0.88–0.94) 25 (0.89/0.76)
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patient-reported outcome measures, either alone or in
combination. Nevertheless, in future research it would
be useful to elicit direct patient input on this issues. An
additional potential limitation of the study is that the
QLQ-C30 pain scale not only assesses severity, but also
interference with daily activities. The larger area under
the curve observed for the pain scale in comparison to
the other three scales that we evaluated probably re-
flects, at least in part, this overlap of the pain scale with
2 of the 3 anchor items; the other three QLQ-C30 do-
mains assess severity only and had overlap with only one
anchor item.
A strength of our study is the large cross-cultural pa-
tient sample. In addition, we employed a rather broad
definition of what makes a symptom or problem clinic-
ally important. We are aware that the set of anchor
items is not exhaustive; however, in our study we found
the three anchor items to be highly correlated (especially
burden and limitations) and it is likely that additional
anchor items (e.g. self-rated importance of a symptom)
would be highly correlated with limitations, burden and
need for help as well. We expect our thresholds to be
fairly robust against changes of the criterion as long as
correlations with our current anchor items are high.
Conclusion
We believe that the thresholds for clinical importance
developed for the four QLQ-C30 scales PF, EF, FA and
PA will facilitate interpretation of these QOL scores on
an individual- and on a group-level. The thresholds can
be used to convert metric QOL scores to symptom
prevalence rates in a meaningful way and thus allow
comparison with prevalence rates collected with other
methods such as clinicians’ ratings. In daily clinical prac-
tice such thresholds can guide identification of patients
with clinically important problems that should be dis-
cussed with the patient. In a next step we will develop
thresholds for clinical importance for all QLQ-C30
scales and the corresponding computer-adaptive mea-
sures currently being developed by the EORTC Quality
of Life Group [21].
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